<DOC>
	<DOCNO>NCT00544310</DOCNO>
	<brief_summary>The objective evaluate safety initial efficacy Omrix Anti-Adhesion ( AA ) kit , Adhexil™ prevent and/or reduce post-operative adhesion patient undergo surgery involve ovary .</brief_summary>
	<brief_title>Pilot Study Evaluating Safety Potential Trends Efficacy Adhexil</brief_title>
	<detailed_description>Adhexil™ contain component form anti-adhesive barrier , BAC Thrombin . Thrombin sterile solution , contain highly purify human thrombin . BAC sterile , solution whose principal component concentrate human fibrinogen . Adhexil™ supply two vial application device .</detailed_description>
	<mesh_term>Ovarian Diseases</mesh_term>
	<criteria>Female patient age 1845 year screen Patients undergo elective laparoscopic surgery due know suspected bilateral ovarian disease Pregnant ( include ectopic pregnancy ) breastfeed patient Patients documented diagnosis cancer Patients lymphatic , hematologic coagulation disorder Patients know suspected hypersensitivity blood , blood product constituent Adhexil™ Patients immunocompromised , possess autoimmune disorder , routinely take anticoagulant . Patients participate another clinical study within 30 day enrolment . Investigator 's opinion patient medically unfit would major risk enrol study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>